Plunkett's Biotech & Genetics Industry Trends & Statistics 2012: A Summary Version of Plunkett's Biotech & Genetics Industry Almanac 2012
Plunkett Research, Ltd.
September 1, 2011 SKU: PLK6505296
|
|
|
This carefully researched report, an excerpt from Plunkett's Biotech & Genetics Industry Almanac 2012, will be your ready-reference guide to the Biotechnology and Genetics Industry. This summary includes our analysis of major trends as well as statistical tables-a tool for strategic planning, business development or industry analysis. Trends analyzed range from the convergence of nanotechnology and biotechnology, to the evolution of breakthrough new drug delivery systems, to the abounding ethical issues connected with biotech. Topics include: biotechnology funding and investments, FDA, gene therapies, personalized medicine, systems biology, clinical trials, stem cells, therapeutic cloning, nanotechnology, agricultural biotechnology (GM seeds), drug delivery systems and ethical issues.
|
- Chapter 1: Major Trends Affecting the Biotech & Genetics Industry
- 1) The State of the Biotechnology Industry Today
- 2) A Short History of Biotechnology
- 3) Ethanol Production Soars, But U.S. Federal Subsidy in Question
- 4) Major Drug Companies Bet on Partnerships With Smaller Biotech Research Firms
- 5) From India to Singapore to China, Nations Compete Fiercely in Biotech Development
- 6) Clinical Trials and Medical Records Processing in India Spark Concerns
- 7) Gene Therapies and Patients’ Genetic Profiles Promise a Personalized Approach to Medicine
- 8) Breakthrough Drugs for Cancer Treatment—Many More Will Follow
- 9) Few New Blockbusters: Major Drug Patents Expire While Generic Sales Growth Continues
- 10) Biotech and Orphan Drugs Pick Up the Slack as Blockbuster Mainstream Drugs Age
- 11) Biogenerics (Follow-on Biologics) are in Limbo in the U.S.
- 12) Breakthrough New Drug Delivery Systems Evolve
- 13) Stem Cells—Multiple Sources Stem from New Technologies
- 14) U.S. Government Stance on Funding for New Stem Cell Research Unclear
- 15) Stem Cells—Therapeutic Cloning Techniques Advance
- 16) Stem Cells—A New Era of Regenerative Medicine Takes Shape
- 17) Nanotechnology Converges with Biotech
- 18) Agricultural Biotechnology Scores Breakthroughs but Causes Controversy/Selective Breeding Offers a Compromise
- 19) Focus on Vaccines
- 20) Technology Discussion—Genomics
- 21) Technology Discussion—Proteomics
- 22) Technology Discussion—Microarrays
- 23) Technology Discussion—DNA Chips
- 24) Technology Discussion—SNPs (“Snips”)
- 25) Technology Discussion—Combinatorial Chemistry
- 26) Technology Discussion—Synthetic Biology
- 27) Technology Discussion—Recombinant DNA
- 28) Technology Discussion—Polymerase Chain Reaction (PCR)
- Chapter 2: Biotech & Genetics Industry Statistics
- Biotech Industry Overview
- The U.S. Drug Discovery & Approval Process
- U.S. FDA New Drug (NDA) and Biologic (BLA) Approvals, 2010
- U.S. Pharmaceutical R&D Spending Versus the Number of New Molecular Entity (NME) Approvals:1993-2009
- Employment in Life & Physical Science Occupations by Business Type, U.S.: May 2010
- Federal R&D & R&D Plant Funding for General Science & Basic Research, U.S. Fiscal Years 2009-2011
- U.S. Exports & Imports of Pharmaceutical Products: 2006-1st Quarter 2011
- U.S. Prescription Drug Expenditures, Aggregate & Per Capita Amounts, Percent Distribution: Selected Calendar Years, 2004-2019
- U.S. Prescription Drug Expenditures: 1965-2019
- Total U.S. Biotechnology Patents Granted per Year by Patent Class: 1977-2010
- Research Funding for Biological Sciences, U.S. National Science Foundation: Fiscal Year 2010-2012
- Global Area of Biotech Crops by Country: 2010
- Biologics & Biotechnology R&D, PhRMA Member Companies: 2009
- Domestic & Foreign Pharmaceutical Sales, PhRMA Member Companies: 1975-2010
- Sales By Geographic Area, PhRMA Member Companies: 2009
- Domestic U.S. Biopharmaceutical R&D Breakdown, PhRMA Member Companies: 2009
- Domestic Biopharmaceutical R&D Scientific, Professional & Technical Personnel by Function, PhRMA Member Companies: 2009
- Domestic U.S. Biopharmaceutical R&D & R&D Abroad, PhRMA Member Companies: 1970-2010
Share this report
Other tasks Related Markets Nanomedicine Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
